Abstract
Objective: The Physician Payments Sunshine Act (PPSA) requires reporting of financial payments by pharmaceutical and medical device companies to teaching hospitals and individual physicians in the US. Industry payments made to psychiatrists were quantified. Methods: Using the 2016–2017 Sunshine Act Open Payments database, general payments made to psychiatrists were descriptively analyzed. The number of psychiatrists who received payments, and median number, value (in US dollar), and nature of payments to psychiatrists were quantified. Top 10 manufacturers who paid the most to psychiatrists were also reported. Results: Over half of active psychiatrists (55.7%) received some form of payments from pharmaceutical manufacturers. Of these, top 2.8% of psychiatrists received 82.6% of the payments. Pharmaceutical manufacturers provided 812,877 payments worth $110,512,607.18 to 26,422 psychiatrists in the US. Compensation for services (e.g., speaker’s bureaus) and consulting fees altogether constituted 71.4% of the total payment, with a median value of $1725.00 and $700, respectively. Among all psychiatrists who received payments, manufacturers that paid the most included Otsuka Pharmaceuticals, Alkermes, and Sunovion Pharmaceuticals. Conclusions: The PPSA was created to foster transparent disclosure of any financial relationship between physicians and industry. Findings highlight that many active psychiatrists receive payments from pharmaceutical industry and payment forms were varied (e.g., food/beverage, educational materials, and compensation for services).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 526-530 |
| Number of pages | 5 |
| Journal | Administration and Policy in Mental Health and Mental Health Services Research |
| Volume | 47 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2020 |
Bibliographical note
Funding Information:This work was supported in part by Grant Number T32AG019134 from the National Institute on Aging (NIA) (TGR) and Grant Number K12HS023000 from the Agency for Healthcare Research and Quality (AHRQ) (STW). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA or AHRQ. We also acknowledge support from the American Foundation for Suicide Prevention, Brain and Behavior Research Foundation (formerly NARSAD), the Patient-Centered Outcomes Research Institute, and the Robert E. Leet and Clara Guthrie Patterson Foundation (STW).
Funding Information:
Each author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Wilkinson receives or has received in the last 36 months research funding from Janssen Pharmaceuticals and expects to receive research funding from Sage Therapeutics. He has consulted for Janssen Pharmaceuticals.
Funding Information:
This work was supported in part by Grant Number T32AG019134 from the National Institute on Aging (NIA) (TGR) and Grant Number K12HS023000 from the Agency for Healthcare Research and Quality (AHRQ) (STW). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA or AHRQ. We also acknowledge support from the American Foundation for Suicide Prevention, Brain and Behavior Research Foundation (formerly NARSAD), the Patient-Centered Outcomes Research Institute, and the Robert E. Leet and Clara Guthrie Patterson Foundation (STW).
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
Keywords
- Centers for Medicare and Medicaid Services
- Marketed drugs
- Open payments
- Pharmaceutical industry
- Psychiatrist
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, U.S. Gov't, P.H.S.
- Research Support, Non-U.S. Gov't
